Congenital HCMV infection is the most frequent congenital infection, with an incidence of 0.2-2.5% among all live births. About 11% of infected newborns show symptoms at birth, including hepatosplenomegaly, thrombocytopenia, neurologic involvement, hearing impairment and visual deficit. Moreover, 5-25% of the asymptomatic congenital HCMV-infected neonates will develop sequelae over months or even years. The relevant social burden, the economic costs of pre-natal screening, post-natal diagnosis, follow-up and possible therapy, although still limited, are the major factors to be considered. Several types of vaccines have been explored in order to develop an effective and safe HCMV vaccine: live attenuated, subunit, vectored, peptide, DNA, and subviral ones, but none are available for use. This review illustrates the different vaccine types studied to date, focusing on the possible vaccination strategy to be implemented once the HCMV vaccine is available, in terms of target population. Copyright © by BIOLIFE, s.a.s.

Is HCMV vaccine an unmet need? The state of art of vaccine development / S., Chiurchiu; F. I., Calo Carducci; F., Rocchi; A., Simonetti; G., Bonatti; S., Salmaso; Melchiorri, Daniela; L., Pani; P., Rossi. - In: INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY. - ISSN 0394-6320. - ELETTRONICO. - 26:1(2013), pp. 15-26.

Is HCMV vaccine an unmet need? The state of art of vaccine development

MELCHIORRI, Daniela;
2013

Abstract

Congenital HCMV infection is the most frequent congenital infection, with an incidence of 0.2-2.5% among all live births. About 11% of infected newborns show symptoms at birth, including hepatosplenomegaly, thrombocytopenia, neurologic involvement, hearing impairment and visual deficit. Moreover, 5-25% of the asymptomatic congenital HCMV-infected neonates will develop sequelae over months or even years. The relevant social burden, the economic costs of pre-natal screening, post-natal diagnosis, follow-up and possible therapy, although still limited, are the major factors to be considered. Several types of vaccines have been explored in order to develop an effective and safe HCMV vaccine: live attenuated, subunit, vectored, peptide, DNA, and subviral ones, but none are available for use. This review illustrates the different vaccine types studied to date, focusing on the possible vaccination strategy to be implemented once the HCMV vaccine is available, in terms of target population. Copyright © by BIOLIFE, s.a.s.
2013
target population; hcmv; vaccine
01 Pubblicazione su rivista::01a Articolo in rivista
Is HCMV vaccine an unmet need? The state of art of vaccine development / S., Chiurchiu; F. I., Calo Carducci; F., Rocchi; A., Simonetti; G., Bonatti; S., Salmaso; Melchiorri, Daniela; L., Pani; P., Rossi. - In: INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY. - ISSN 0394-6320. - ELETTRONICO. - 26:1(2013), pp. 15-26.
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/523669
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact